RegeneExo™ is a lyophilised extracellular vesicle preparation characterised through complementary methods. For lot 20260501, the COA reports 8.7 × 10¹¹ particles and a particle-size result of 121.1 nm; TEM showed the stated morphology, and Western blot detected CD63, CD81 and CD9.
Production begins with a controlled cell platform, followed by collection, isolation, purification, lyophilisation and lot-specific quality review. Each stage is designed to protect material identity and create a consistent powder format for storage and handling.
NTA measures particle quantity and size distribution; TEM assesses morphology; Western blot checks EV-associated markers. In the reviewed EXO1 lot, particle quantity exceeded the stated specification of ≥5.0 × 10¹¹ particles, while pH was 7.26, as reported in the COA.
The white-to-yellowish powder is stored at or below −20°C and carries a one-year shelf life under the stated conditions. Lot 20260501 met the listed sterility, mycoplasma, endotoxin (<0.25 EU/mL) and infectious-virus requirements.
Extracellular vesicle science is explored in relation to skin quality, visible revitalisation and professional-care concepts. Any finished-product claim or route of use must be supported and permitted in the relevant market.
Research examines how extracellular-vesicle-associated components interact with cellular communication and tissue-response pathways. The page presents this as a field of study, not as a treatment claim for wounds, burns or scars.
Beyond aesthetics, extracellular vesicles are widely studied across regenerative biology. Ruimei’s technology page focuses on material characterisation, quality control and responsible interpretation of emerging research.
HAVE A QUESTION ABOUT RUIMEI, OUR PRODUCTS OR OUR TECHNOLOGIES? LEAVE YOUR DETAILS AND OUR TEAM WILL RESPOND.